Suppr超能文献

细胞毒性 T 淋巴细胞相关抗原 4 多态性与哮喘风险:荟萃分析。

Cytotoxic T-lymphocyte associated antigen 4 polymorphisms and asthma risk: a meta-analysis.

机构信息

Department of Respiratory Disease, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China.

出版信息

PLoS One. 2012;7(7):e42062. doi: 10.1371/journal.pone.0042062. Epub 2012 Jul 26.

Abstract

BACKGROUND

A number of studies assessed the association of cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) gene polymorphisms with asthma in different populations. However, the results were contradictory. We performed a meta-analysis to examine the association between CTLA-4 polymorphisms and asthma susceptibility.

METHODS

Pubmed, EMBASE, HuGE Navigator, and Wanfang Database were searched. Data were extracted independently by two reviewers. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations.

RESULTS

Seventeen studies involving 6378 cases and 8674 controls were included. Significant association between +49 A/G polymorphism and asthma was observed for AA vs. AG+GG (OR = 1.18, 95% CI 1.01-1.37, P = 0.04). There were no significant associations between -318 C/T, -1147 C/T, CT60 A/G, -1722 C/T, or rs926169 polymorphisms and asthma risk.

CONCLUSIONS

This meta-analysis suggested that the +49 A/G polymorphism in CTLA-4 was a risk factor for asthma.

摘要

背景

多项研究评估了细胞毒性 T 淋巴细胞相关抗原 4(CTLA-4)基因多态性与不同人群哮喘之间的关联。然而,结果存在矛盾。我们进行了荟萃分析,以检验 CTLA-4 多态性与哮喘易感性之间的关联。

方法

检索 Pubmed、EMBASE、HuGE Navigator 和万方数据库。由两名评审员独立提取数据。使用比值比(OR)及其 95%置信区间(CI)来评估关联的强度。

结果

纳入了 17 项研究,涉及 6378 例病例和 8674 例对照。+49 A/G 多态性与 AA 相比 AG+GG 与哮喘显著相关(OR=1.18,95%CI 1.01-1.37,P=0.04)。-318 C/T、-1147 C/T、CT60 A/G、-1722 C/T 或 rs926169 多态性与哮喘风险之间无显著关联。

结论

这项荟萃分析表明 CTLA-4 中的+49 A/G 多态性是哮喘的一个危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c1/3406027/ed224398fbf0/pone.0042062.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验